#USA #Cambridge #RNA Drugs #Prix Galien #Innorna

Innorna Nominated for Prestigious Award

On August 14, 2026, Innorna, a clinical-stage biotechnology company, announced its nomination for the esteemed 2026 Prix Galien USA Best Startup Award. This recognition highlights Innorna's innovative approach in developing RNA-based medications, reflecting the company’s unwavering commitment to enhancing healthcare solutions.

Innovative mRNA-LNP Platform

Innorna is distinguished in the biotech sector for its advanced messenger RNA (mRNA) lipid nanoparticle (LNP) platform. This platform sets the foundation for its diverse clinical pipeline, which includes not only vaccines but also therapeutics aimed at critical healthcare challenges. The company's flagship project, IN026, showcases a novel mRNA therapy designed specifically for treating refractory gout, with a primary goal of lowering uric acid levels in patients.

In March 2026, the U.S. FDA granted IN026 an Investigational New Drug (IND) approval, a significant milestone that allows for expanded possibilities of mRNA-based protein substitutes for common chronic conditions. This approval underscores the potential impact of mRNA technology in treating various diseases, positioning Innorna at the forefront of biopharmaceutical innovation.

A Testament to Excellence

The Prix Galien is often referred to as the “Nobel Prize of the biopharmaceutical industry.” It honors unparalleled achievements in medical innovations that greatly benefit human health. Selection committees for these prestigious awards comprise renowned biomedical scientists, industry leaders, and Nobel laureates who assess nominees based on pivotal contributions to healthcare advancements.

Dr. Linxian Li, founder and CEO of Innorna, expressed profound gratitude for the nomination, stating, “It is an honor to be recognized in the category of Best Startup. This nomination is a reflection of the strides our team has made in advancing our clinical pipeline, which has involved years of dedicated platform development. It reminds us of our commitment to developing RNA medicines that can offer better treatment options and improve the quality of life for patients globally.”

Upcoming Award Ceremony

The winners of the Prix Galien USA Awards 2026 will be revealed at an award ceremony to be held on October 29, 2026, at the American Museum of Natural History in New York City. This event will celebrate the remarkable achievements in biopharmaceutical advancements and highlight the transformative power of biotechnology in modern medicine.

About Innorna

Founded with a vision to revolutionize the pharmaceutical landscape, Innorna is pioneering groundbreaking RNA medicines. The company is committed to accelerating a positive cycle of platform and pipeline innovations that enhance the quality of life globally. With a significant and expanding portfolio of intellectual property, Innorna has established a proprietary and differentiated RNA delivery and engineering platform. This encompasses a rationally designed library of over 6,000 chemically diverse ionizable lipids, targeted LNP delivery systems, and mRNA technologies. The company’s vertically integrated capabilities—from discovery to cGMP-compliant manufacturing—allow for deep technical expertise, accelerated development timelines, and high capital efficiency. Innorna is advancing a robust RNA pipeline in areas such as chronic disease therapeutics, in vivo immunotherapies, and vaccines, having raised an impressive $150 million in funding to date.